New pill could tame rare hormone disorder

NCT ID NCT05907291

Completed Disease control Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new oral drug called atumelnant in 38 adults with classic congenital adrenal hyperplasia, a genetic condition causing hormone imbalances. The drug works by blocking a hormone receptor to lower excess adrenal hormones. Researchers measured safety, side effects, and changes in hormone levels over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atumelnant (CRN04894), an oral drug that blocks a hormone receptor to reduce excess adrenal hormones
What this could lead to: If successful, this could lead to a new oral treatment option for congenital adrenal hyperplasia, potentially reducing the need for high-dose steroids.
What could go wrong: This is an early Phase 2 trial with only 38 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic congenital adrenal hyperplasia classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSIC CONGENITAL ADRENAL HYPERPLASIA CONGENITAL ADRENAL HYPERPLASIA

Contacts and locations

Locations

Crinetics Study Site

Pasadena, California, 91105, United States
Crinetics Study Site

Ann Arbor, Michigan, 48109, United States
Crinetics Study Site

Minneapolis, Minnesota, 55454, United States
Crinetics Study Site

St Louis, Missouri, 63110, United States
Crinetics Study Site

Morehead City, North Carolina, 28557, United States
Crinetics Study Site

Cleveland, Ohio, 44195, United States
Crinetics Study Site

Philadelphia, Pennsylvania, 19104, United States
Crinetics Study Site

East Providence, Rhode Island, 02915, United States
Crinetics Study Site

Córdoba, Córdoba Province, 5000, Argentina
Crinetics Study Site

Buenos Aires, C1180, Argentina
Crinetics Study Site

Curitiba, Paraná, 80030-110, Brazil
Crinetics Study Site

Rio de Janeiro, Rio de Janeiro, 20231-092, Brazil
Crinetics Study Site

Rio de Janeiro, Rio de Janeiro, 20551-030, Brazil
Crinetics Study Site

Porto Alegre, Rio Grande do Sul, 90410-000, Brazil
Crinetics Study Site

Botucatu, São Paulo, 18618-686, Brazil
Crinetics Study Site

Ribeirão Preto, São Paulo, 14051-140, Brazil
Crinetics Study Site

São Paulo, São Paulo, 04024-002, Brazil
Crinetics Study Site

São Paulo, 05403-000, Brazil
Crinetics Study Site

Munich, Bavaria, 80336, Germany
Crinetics Study Site

Bangalore, Karnataka, 560054, India
Crinetics Study Site

Vellore, Tamil Nadu, 632004, India
Crinetics Study Site

Naples, 80131, Italy
Crinetics Study Site

Roma, 00161, Italy
Crinetics Study Site

Rozzano, 20089, Italy
Crinetics Study Site

Sheffield, South Yorkshire, S10 2RX, United Kingdom
Crinetics Study Site

Coventry, West Midlands, CV22DX, United Kingdom
Crinetics Study Site

London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.